$ANTX News

Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target

AN2 Therapeutics Inc (NASDAQ:ANTX) Pipeline Progress Outshines Slight Q1 Earnings Miss

AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies Dated April 9, 2026; Co. May Offer And Sell Common Stock Up To $80M Through Jefferies

AN2 Therapeutics Files Prospectus To Offer And Sell Up To $300M Of Securities

AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies; Co. May Issue And Sell From Time To Time Up To An Aggregate Of $80M Of Shares Of The Company's Common Stock

AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027

AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate

AN2 Therapeutics Stock Cools Off After 90% Rally

Monday's session: top gainers and losers

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

AN2 Therapeutics shares are trading higher after the company announced it entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million.

AN2 Therapeutics shares are trading higher after the company announced it entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million.

AN2 Therapeutics Raises $40M Through Private Placement Of 8,245,611 Common Shares At $2.85, With Coastlands, Commodore And Vivo Capital Participating

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

AN2 Therapeutics Plans Phase 2 Trial Of Oral Epetraborole In Polycythemia Vera; Study To Begin Q3 2026 With Potential For Data Readouts As Early As Q4 And Throughout 2027

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

The FDA Clears Oregon Health & Science University's Investigational New Drug Application To Proceed With Investigator-Initiated Trial Of AN2 Therapeutics' Epetraborole For Mycobacterium Abscessus Lung Disease, Patient Enrollment To Start In Q1 2026

AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights